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Objective: Provide recommendations to the cystic ﬁbrosis (CF) community to facilitate timely referral for lung
transplantation for individuals with CF.
Methods: The CF Foundation organized a multidisciplinary committee to develop CF Lung Transplant Referral
Consensus Guidelines. Three workgroups were formed: timing for transplant referral; modiﬁable barriers to
transplant; and transition to transplant care. A focus group of lung transplant recipients with CF and spouses
of CF recipients informed guideline development.
Results: The committee formulated 21 recommendation statements based on literature review, committeemem-
ber practices, focus group insights, and in response to public comment. Critical approaches to optimizing access
to lung transplant include early discussion of this treatment option, assessment for modiﬁable barriers to trans-
plant, and open communication between the CF and lung transplant centers.
Conclusions: These guidelines will help CF providers counsel their patients and may reduce the number of indi-
viduals with CF who die without consideration for lung transplant.
© 2019 TheAuthor(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
In the current era of improving life expectancy for individuals with
cystic ﬁbrosis (CF), pulmonary disease remains the primary cause of se-
vere morbidity and mortality. Nevertheless, many individuals with CF
die from respiratory failure without referral for lung transplantation
(LTx) [1,2]. LTx referral is best initiated for individuals with advanced
but not end-stage lung disease; emergent referral (Table 1) does not
allow time for careful consideration of the LTx option and is not univer-
sally available. Early referral for LTx gives individualswith CF the oppor-
tunity to learn more about the risks and beneﬁts of LTx, both generally
and speciﬁc to their clinical situation, so they can make informed deci-
sions. While LTx is not the right option for every individual with CF,
the discussion is important for everyone. Early LTx referral increases
the likelihood of an individual being a candidate for transplant by giving
the patient an understanding of their speciﬁc barriers to LTx, as well as
an opportunity to address those barriers. While many individuals who
meet these Consensus Guidelines' criteria for referral will be too early
for listing, it is important to recognize that referral does not necessarily
lead to a full evaluation or listing, but instead gives individuals with CF,
their families (“family” will be used throughout this document to refer
to the patient's desired support system, which may or may not include
relatives), and the CF care team access to the transplant-speciﬁc exper-
tise of the LTx team. Progressing from routine CF care to LTx can be
viewed as a transition. As modeled by the transition from pediatric to
adult care, it is facilitated by education, communication and support
for both the individual and family. Communication between the CF
Center and Transplant Center is essential for a smooth transition. Early
referral for LTx allows individuals to be medically, psychosocially, and
ﬁnancially prepared for LTx should the need arise. Late referral may
lead to death on the transplant waiting list [2] or increased morbidity
and/or mortality in the immediate post-operative period stemming
from severe pre-operative illness [3]. While there may not be a perfect
“window” for referral, an inclusive approach reduces the likelihood
that eligible patients miss their opportunity for LTx. The goal of these
Consensus Guidelines is to provide pragmatic recommendations and
guidance to the CF community to facilitate better identiﬁcation and
timely referral, listing, and transplantation of those individuals with CF
who have advanced lung disease (ALD).
2. Methods
The CF Foundation invited a multidisciplinary team including adult
and pediatric CF and transplant pulmonologists, a clinical psychologist,
a clinical social worker, a transplant recipient with CF, a former CF
nurse, and a transplant coordinator to participate in development of
consensus guidelines. The committee met for a virtual kickoff meeting
on September 26, 2017 to determine the scope of the work and divide
into three workgroups focusing on: timing for transplant referral; early
referral and modiﬁable barriers; and transition to transplant care. Sev-
eral PICO (Population, Intervention, Control, Outcome) questions were
developed by each workgroup. These PICO questions were reviewed
by theworkgroup leaders and chairs to ensure there was no overlap be-
tween the working groups. The workgroups performed literature
searches in PubMed. Information about the speciﬁc literature searches
can be found in the Online Supplement. Theworkgroup leads and chairs
met monthly to discuss the progress of their workgroups and address
any questions and potential overlap between the workgroups.
Information was also gathered from a focus group of CF transplant
recipients and spouses of recipients to inform the recommendation
statements, tables and ﬁgures presented in this manuscript.
The workgroups developed draft recommendations based on data
from the relevant publications identiﬁed in the literature searches and
learnings from the focus group. Workgroups discussed the recommen-
dations on monthly phone calls. The committee reconvened on May
11, 2018 to revise and vote on the draft recommendation statements.
An a priori voting threshold of 80% agreement was established. The
Table 1
Explanation of terminology.
Lung transplant referral The act of sending a request and transmitting
medical records to a lung transplant center to
assess an individual's candidacy for lung
transplantation, usually through a clinic visit at
the transplant center. In addition to the lung
transplant assessment itself, the referral serves
as an opportunity for the individual with cystic
ﬁbrosis (CF), their family, and the CF care team
to gain access to the expert opinion of the lung
transplant center. Depending on the situation
and transplant program practices, it may result
in a brief evaluation with a focus on education,
discussion of potential barriers, or a complete
evaluation.
Lung transplant evaluation Consultation and diagnostic testing to assess
disease severity and identify whether speciﬁc
barriers to lung transplantation exist and
whether those barriers are modiﬁable. The
evaluation involves a comprehensive
assessment of the individual's medical condition
and comorbidities, psychosocial situation, and
ﬁnancial/insurance resources.
Lung transplant listing Placement on the lung transplant waitlist as an
appropriate candidate for lung transplant to
await a suitable donor. Listing is dependent on
the completion of an evaluation, approval by a
lung transplant selection committee, and
insurance coverage for the transplant. A patient's
status on the list is ﬂuid and can change based on
disease severity or the development of
contraindications after listing.
Early referral Referral of an individual prior to the medical
need for lung transplantation.
Timely referral Referral of an individual with medical
indications for lung transplantation, likely
requiring listing, without an urgent indication
for transplant (e.g. acute respiratory failure).
Late referral Referral of an individual for transplant
consideration when the individual is too sick to
undergo routine transplant evaluation (e.g.
emergent referral for an individual in acute
respiratory failure). Late referral may lead to
death without transplant because of inadequate
time to proceed with listing or limited lung
donor availability, or to poor post-transplant
outcomes (e.g. increased post-operative
morbidity/mortality) in the setting of severe
pre-transplant illness.
Consultation with lung
transplant center
Physician to physician conversation via phone,
email or in-person about the individual with CF.
Communication between CF
and lung transplant centers
Phone call, email, or medical record notes to the
lung transplant team (MD, RN, social work,
dietician, as indicated) from the CF care team
and vice versa.
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committee discussed each recommendation statement, and revised the
phrasing of the statement as needed, prior to voting. After this meeting,
the chairs and workgroup leads drafted the manuscript. The draft man-
uscript was reviewed and approved by the committee and focus group.
On September 19, 2018, the lung transplant referral guidelines were
distributed for public comment.
The committee reviewed the results of the public comment. Based
on feedback received, the committee reconsidered eight recommenda-
tions (original statement numbers 1, 6, 9, 16, 17, 19, 20, and 21).
These statements were revised and voted on again on a virtual meeting
on December 7, 2018. Committee members who were unable to attend
this meeting sent their votes to the guidelines specialist who tallied the
results for the chairs.
2.1. Focus group
A focus group of seven CF transplant recipients and two spouses of
recipients (hereafter referred to as “the focus group”) was organized
to identify priority issues from the patient's perspective. Although
focus group content and data synthesis are qualitative by nature, these
ancillary data sources can provide informative clinical data [4,5]. The
focus group participated in seven, one-hour long video-calls led by a
transplant psychologist (PJS) and an adultwith CF (AL). Following an in-
troductory session during which thematic content was identiﬁed and
analyzed, the focus group participated in ﬁve content-speciﬁc calls
and one summary review call. Themes identiﬁed during the introduc-
tory call included: 1) timing of transplant information delivered in CF
Clinic, 2) individual's transplant-related expectations, 3) treatment
team transition issues (from CF to transplant care), 4) stigma associated
with the need for transplantation, and 5) concerns regarding social sup-
port during the transition to transplant. All calls were video- and audio-
recorded in order to facilitate re-analysis by focus group leaders.
3. Discussion of recommendation statements
There was 100% agreement among Lung Transplant Referral Com-
mittee members with the consensus guideline recommendation state-
ments as published (listed in Table 2).
1. The CF Foundation recommends routine clinician-led efforts to dis-
cuss disease trajectory and treatment options, including a discussion
of lung transplantation.
For individuals with CF and ALD, LTx confers a survival beneﬁt [6]
and post-transplant survival is increasing, with the current Interna-
tional Society for Heart and Lung Transplantation (ISHLT) registry
report documenting 9.5 years median survival among adults with CF
[7]. Therefore, periodic discussion of LTx is recommended to help de-
stigmatize the procedure. Discussing LTx with individuals with normal
lung function or only mildly reduced forced expiratory volume in one
second (FEV1) should be seen as a form of anticipatory guidance for in-
dividuals and their families. The routine discussion of LTx can include an
acknowledgement that the individual does not require transplant,
which may relieve unspoken anxiety. Numerous members of the focus
group noted that early introduction and normalization of LTx facilitated
a more effective transition/referral process. In contrast, when LTx was
introduced in the context of clinical deterioration, it was associated
with increased fear, denial, and potential delay and/or avoidance of im-
portant clinical elements of care.Many focus groupmembers character-
ized their impressions of LTx as ‘a death sentence’, ‘the beginning of the
end’, or with similarly negative connotations, despite the improving
post-transplant survival outcomes (Table 3). It was also noted in the
focus group that individuals' feelings toward transplant strongly mir-
rored that of their physician(s). For example, a strong association was
noted between physicians who reportedly exhibited a negative bias to-
ward transplant and individuals who felt fear, anxiety, and a sense of
Table 2
Recommendation Statements.
Recommendation % Consensus among
Transplant
Referral Guidelines
Committee
(N= 16)
1 The CF Foundation recommends routine clinician-led
efforts to discuss disease trajectory and treatment
options, including a discussion of lung transplantation.
100%
2 The CF Foundation recommends CF care team initiated
discussion regarding lung transplantation with all
individuals with CF and an FEV1 b50% predicted.
100%
3 The CF Foundation recommends the use of up-to-date
CF-speciﬁc transplant resources to promote
understanding of the transplant journey and to
minimize misconceptions regarding outcomes.
100%
4 The CF Foundation recommends that CF clinicians
develop relationships with peers at partnering
transplant centers to:
• optimize the transition to transplant, starting with
referral
• understand transplant center-speciﬁc practices,
including navigating complex socioeconomic barriers
to transplant
• maintain ongoing communication about clinical sta-
tus of individuals listed or approaching transplant
listing
100%
5 The CF Foundation recommends that the individual's CF
care team elicit and address CF-speciﬁc psychosocial
and physical concerns about lung transplantation to
facilitate transition to transplant.
100%
6 The CF Foundation recommends that modiﬁable
barriers to lung transplantation be addressed
preemptively to optimize transplant candidacy;
however, unresolved barriers should not preclude
referral. Potentially modiﬁable barriers may include but
are not limited to: nutritional status, diabetes
management, physical inactivity or deconditioning,
adherence behaviors, mental health issues, substance
use, and psychosocial factors.
100%
7 The CF Foundation recommends the CF and lung
transplant care teams acknowledge and provide
support for mental health concerns regarding the
referral and evaluation process for transplant that are
unique to individuals with CF.
100%
8 For individuals with CF who are 18 years of age and
older, the CF Foundation recommends lung transplant
referral no later than when:
• FEV1 is b50% predicted and rapidly declining (N20%
relative decline in FEV1 within 12 months)
OR
• FEV1 is b40% predicted with markers of shortened
survival (including those noted in recommendations
#12–16)
OR
• FEV1 is b30% predicted
100%
9 For individuals with CF who are under the age of
18 years, the CF Foundation recommends lung
transplant referral no later than when:
• FEV1 is b50% predicted and rapidly declining (N20%
relative decline in FEV1 within 12 months)
OR
• FEV1 is b50% predicted with markers of shortened
survival (including those noted in recommendations
#12–16)
OR
• FEV1 is b40% predicted
100%
10 For individuals with CF and an FEV1 b 40% predicted, the
CF Foundation recommends an annual 6-min walk test
(6MWT), assessment of need for supplemental oxygen,
and venous blood gas to screen for markers of severe
disease that may warrant transplant referral.
100%
11 For individuals with CF who are 18 years of age and
older with FEV1 b 40% predicted, the CF Foundation
recommends a baseline echocardiogram to screen for
100%
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personal failure. In contrast, individuals that reported having physicians
who regarded transplant more positively, and who approached trans-
plant as a treatment option that extends life for end-stage CF, felt
more informed, conﬁdent, and optimistic about their future quality of
life. Several speciﬁc recommendations in the consensus guidelines
may help accomplish the broader goal to destigmatize discussion of
LTx, including earlier physician-patient discussions of LTx as a treat-
ment option for end-stage CF, the use of up-to-date sources of informa-
tion related to LTx [8,9], and alternative discussion points for clinicians
(Table 3). Discussion of disease trajectory and treatment options serves
as an opportunity to discuss treatment goals,whichwould inevitably in-
clude the possibility of LTx [10,11].
2. The CF Foundation recommends CF care team initiated discussion
regarding lung transplantation with all individuals with CF and an
FEV1 b50% predicted.
While many studies have demonstrated an association between
FEV1 and mortality [12–18], FEV1 is an imperfect marker of disease se-
verity. Survival with low lung function is improving, and some individ-
uals with CF live for many years with severely reduced lung function
while others die quickly following a decline in FEV1 [1,12,19,20]. Deter-
mining which FEV1 (best, worst, “baseline”, or during an exacerbation)
should prompt action is challenging. Expert consensus concluded that
an FEV1 b 50% predicted, regardless of the context, should prompt dis-
cussion of LTx as a potential therapeutic option (Fig. 1). This discussion
serves as an opportunity to identify barriers to LTx, to clarify the individ-
ual's goals of care (Table 4) and could be reasonably broached by any
member of the care team. Some potential barriers to LTx could require
years of work to correct in order for an individual to become an accept-
able candidate – early discussion may permit this opportunity.
3. The CF Foundation recommends the use of up-to-date CF-speciﬁc
transplant resources to promote understanding of the transplant
journey and to minimize misconceptions regarding outcomes.
Individuals with CF and their families should have access to contem-
porary, CF-speciﬁc information regarding LTx in order to optimize their
understanding of potential transplant outcomes. These data can be
found on the websites of several organizations, including the Cystic Fi-
brosis Foundation (CFF.org), the ISHLT (ishlt.org), the Scientiﬁc Registry
of Transplant Recipients (SRTR.org), and the United Network for Organ
Sharing (UNOS) (unos.org). The annual ISHLT Registry Report provides
international disease-speciﬁc survival statistics and other clinical out-
comes data. Many transplant centers have institutional websites that
describe local practices and provide contact information for the trans-
plant team. Decision aids or other technology-based sources of informa-
tion could be useful to highlight misconceptions/misunderstandings
and facilitate an accurate fund of knowledge regarding LTx [21–24].
Another potential resource is connecting people with CF with individ-
uals who have undergone LTx to address concerns regarding transplan-
tation [9].
4. The CF Foundation recommends that CF clinicians develop relation-
ships with peers at partnering transplant centers to:
• optimize the transition to transplant, starting with referral
• understand transplant center-speciﬁc practices, including navigat-
ing complex socioeconomic barriers to transplant
• maintain ongoing communication about clinical status of individ-
uals listed or approaching transplant listing
Identifying peers at partnering transplant centers allows for im-
proved communication and facilitates continuity of care. CF care
teams can deliver the best care to individuals at their home CF Center
when they are aware of the partnering lung transplant center's prac-
tices. Clear communication of the necessary medical information at
the time of transplant referral will streamline the process and increase
efﬁciency for both teams (see CFF.org for a transplant referral form tem-
plate). CF teams should develop an understanding of the partnering
transplant centers' approach to multiple organ transplantation (e.g.
lung/liver, lung/kidney) and preferred timing of referral in those cases.
Maintaining a relationship between the CF team and partnering trans-
plant team allows for a smooth transplant referral and ongoing co-
management of individuals in the pre-transplant phase. CF providers,
including all members of the CF care team, can reinforce the importance
Table 2 (continued)
Recommendation % Consensus among
Transplant
Referral Guidelines
Committee
(N= 16)
pulmonary hypertension.
12 The CF Foundation recommends lung transplant
referral, regardless of FEV1, when there are markers of
shortened survival, including:
• 6MWT distance b400 m
OR
• hypoxemia (at rest or with exertion)
OR
• hypercarbia (PaCO2 N 50 mmHg, conﬁrmed on arte-
rial blood gas)
OR
• pulmonary hypertension (PA systolic pressure
N 50 mmHg on echocardiogram or evidence of right
ventricular dysfunction in the absence of a tricuspid
regurgitant jet)
100%
13 The CF Foundation recommends lung transplant
referral for adults with CF with a BMI b18 and FEV1
b 40% predicted while concurrently working to
improve nutritional status.
100%
14 The CF Foundation recommends lung transplant
referral for individuals with FEV1 b 40% predicted and
N 2 exacerbations per year requiring IV antibiotics or 1
exacerbation requiring positive pressure ventilation
regardless of FEV1.
100%
15 The CF Foundation recommends lung transplant
referral for individuals with FEV1 b 40% predicted and
massive hemoptysis (N240 mL) requiring ICU
admission or bronchial artery embolization.
100%
16 The CF Foundation recommends lung transplant
referral for individuals with FEV1 b 40% predicted and
pneumothorax.
100%
17 For females with CF, especially those who are younger,
the CF Foundation recommends special consideration
for lung transplant referral even when other thresholds
have not been met.
100%
18 For individuals with short stature (height b162 cm), the
CF Foundation recommends special consideration for
lung transplant referral even when other thresholds
have not been met.
100%
19 The CF Foundation recommends CF clinician
consultation with local and geographically distant lung
transplant centers for individuals with microorganisms
that may pose a risk for lung transplantation (e.g.
Burkholderia cepacia complex, nontuberculous
mycobacterium, certain molds such as scedosporium).
100%
20 Before determining that an individual is not a
transplant candidate the CF Foundation recommends
consultation with at least two transplant centers, one of
which should have experience addressing the
individual's potential contraindications to
transplantation.
100%
21 For transplant candidates, the CF Foundation
recommends communication between the CF and lung
transplant care teams at least every 6 months and with
major clinical changes.
100%
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of ongoing work by the individuals with CF and caregivers to address
outstanding concerns. Having connections at multiple transplant cen-
ters may be valuable in the setting of insurance limitations and the
widely varying practices and requirements of lung transplant programs
across the United States (US).
5. The CF Foundation recommends that the individual's CF care team
elicit and address CF-speciﬁc psychosocial and physical concerns
about lung transplantation to facilitate transition to transplant.
Numerous psychosocial, physical, and care-related concerns
emerged from the focus group as being particularly salient among indi-
viduals with CF. Increased complexity of care, the potential for de-
centralization of care (leaving the CF center), worsening impairments
in quality of life at a young age, the potential loss of CF identity, concerns
regarding family planning, relationship issues, and education/career
could inﬂuence their approach to the transplant process [25]. There is
decreased access to referral, listing and LTx for individuals with CF and
lower socioeconomic status [26,27]. Geographic disparities in access to
LTx are an important consideration for people with CF [26]. A recent
study demonstrated increased risk of death without LTx and a younger
age at death for Hispanic individuals with CF [28]. Providing psychoso-
cial support to individuals with CF during the transition requires an un-
derstanding of these (and other) CF-speciﬁc psychosocial concerns.
Care and assistance from family is vital for individuals on the transplant
journey. LTx teams also need to acknowledge and address CF-speciﬁc
concerns related to transplant, as some issues may persist post-
transplant.
6. The CF Foundation recommends that modiﬁable barriers to lung
transplantation be addressed preemptively to optimize transplant
candidacy; however, unresolved barriers should not preclude refer-
ral. Potentially modiﬁable barriers may include but are not limited
to: nutritional status, diabetes management, physical inactivity or
deconditioning, adherence behaviors, mental health issues, sub-
stance use, and psychosocial factors.
The number of individuals with CF who die each year without lung
transplant referral remains signiﬁcant [1]. A survey of physicians in
the US demonstrated that potentially modiﬁable barriers are a frequent
reason for non-referral [29]. Modiﬁable barriers to transplant should be
identiﬁed preemptively in CF clinic, potentially years prior to the need
for LTx, but these do not need to be fully resolved prior to a referral
(Table 4). Learning about barriers to transplant directly from the trans-
plant team serves to reinforce the messages given by the CF team and
may prompt increased effort on behalf of the individual with CF to cor-
rect these concerns so that transplantmay be an option. Transplant pro-
viders can articulate how these issues speciﬁcally affect their transplant
candidacy and provide tools and motivation to address these barriers.
The transplant team can provide center-speciﬁc education for indi-
viduals with CF and their families. The transplant program can assess
barriers in the context of transplant candidacy as a whole, and deter-
mine exactly what progress needs to be made in order for someone to
become an acceptable candidate for transplant. Additionally, non-
medical barriers to LTx, including insurance status, geography, ﬁnances,
medical literacy, and limited social support, may inﬂuence not only
when to refer for transplant, but also where to refer. Certain psychoso-
cial factors may take years of work in order to optimize a candidate for
lung transplant.
7. The CF Foundation recommends the CF and lung transplant care
teams acknowledge and provide support formental health concerns
regarding the referral and evaluation process for transplant that are
unique to individuals with CF.
Many focus groupmembers noted that the idea of requiring LTxmay
elicit reﬂexive, internal attributions that the need for transplant reﬂects
Table 3
Focus group-derived themes and considerations for communicationwith individuals with
cystic ﬁbrosis.
Thematic domain Provider exemplars from
focus group
Effective alternative
exemplars for clinicians
Destigmatize the
need for lung
transplantation
- ‘We will think about
transplant when it's
time [for transplant]’
- ‘Transplant is to be
avoided if at all
possible.’
- ‘You're trading one dis-
ease for another.’
- ‘Transplant is often con-
sidered as a next step as
CF worsens.’
- ‘Many individuals with
CF will undergo trans-
plant as a component of
their care when other
therapies no longer
work.’
- ‘What have other pro-
viders told you, if
anything, about the
risks and beneﬁts of
transplant?’
- ‘Tell me your under-
standing of transplant
so that I can help pro-
vide more information.’
- ‘While there are cer-
tainly risks associated
with transplantation,
there is a very good
chance that it will
increase the quality and
length of your life.’
Eliciting and
addressing
CF-related
concerns and
outcomes
-‘Your lungs have failed you.’
-‘We [treatment team] have
failed you.’
-‘You fought hard but lost
the battle.’
-‘Your test results indicate
we need to move forward
with a transplant referral.
We will set up your
appointments.’
- ‘You've fought hard and
done your part. For
many people living with
CF, lung function will
eventually worsen to
the point where we
consider transplant, no
matter how hard you
ﬁght.’
- ‘We have done the best
we can and we now
need to consider trans-
plant as the next step to
best treat your CF.’
- ‘Most people have some
concerns about trans-
plantation. Help me to
understand yours.’
- ‘Your test results sug-
gest that we may need
to consider a transplant
evaluation. What
thoughts do you have
about that possibility?’
Addressing
transplant-related
expectations
- ‘Recipients only live
5 years.’
- ‘Many patients don't do
well after transplant.’
- ‘Transplant is a death
sentence.’
- ‘Everyone's transplant
experience is different
and unique. For people
with CF the median
post-transplant survival
is 9.5 years. That means
that half of the people
who undergo lung
transplantation for CF
live for N9.5 years, many
signiﬁcantly more.
- ‘Individuals with CF
who receive lung trans-
plants show the
greatest health and
quality of life beneﬁts
compared to other lung
transplant recipients.
Although there are
potential complications,
the vast majority are
manageable.’
325K.J. Ramos et al. / Journal of Cystic Fibrosis 18 (2019) 321–333
a failure of their own adherence behaviors. Because the importance of
adherence-related behaviors is often underscored for many individuals
with CF and their families, and these behaviors are often integrally tied
to clinical outcomes, this implicit association may inadvertently elicit
feelings of shame [30,31] or stigma [32]. For example, many individuals
in the focus group characterized coping styles that would ‘ﬁght’ or ‘beat’
CF through vigilant adherence behaviors [33–35]. Care teams are en-
couraged to identify and address individuals' negative self-directed
emotions because they can lead to avoidance of clinical interactions
and delay the receipt of appropriate care [36,37]. Mental health con-
cerns, such as depression and anxiety, should also be assessed through
routine screening at least annually and formal mental health treatment
should be considered if indicated [38]. For most transplant centers,
management of common mental health concerns using psychotropic
medications is not a contraindication for transplantation and may opti-
mize an individual's ability to cope during a period of greater distress
and worsening quality of life. In addition, providers should be aware
that the introduction of uncertainty about patients' eligibility for LTx
may serve to increase ambivalence and ultimately avoidance of
transplant-related knowledge or health decisions [39,40]. Moreover,
depression and anxiety are common among individuals with CF [38]
and, if persistent and inadequately treated, may adversely impact LTx
outcomes [41,42].
8. For individuals with CF who are 18 years of age and older, the CF
Foundation recommends lung transplant referral no later than
when:
• FEV1 is b50% predicted and rapidly declining (N20% relative decline
in FEV1 within 12 months)
OR
• FEV1 is b40% predicted with markers of shortened survival (including
those noted in recommendations #12–16)
OR
• FEV1 is b30% predicted
Because FEV1 is associated with mortality [12–18], FEV1 thresholds
were identiﬁed to prompt further action, including evaluation for
markers of shortened survival and/or lung transplant referral. Markers
of shortened survival include low FEV1, 6-min walk test (6MWT) dis-
tance b400 m, room air hypoxemia (SpO2 b 88% or PaO2 b 55 mmHg,
at rest or with exertion; at sea level), hypercarbia (PaCO2 N 50 mmHg,
conﬁrmed on arterial blood gas), pulmonary hypertension (PA systolic
pressure N 50mmHgon echocardiogramor evidence of right ventricular
dysfunction in the absence of a tricuspid regurgitant jet), BMI b18 kg/m2
for adults (or BMI less than 5th percentile for children), increased
frequency of pulmonary exacerbations (N2 exacerbations per year
requiring IV antibiotics or one exacerbation requiring positive pressure
ventilation), massive hemoptysis, or pneumothorax [1,12–19,25,43,44].
Additionally, a low physical functioning score on the CFQ-R question-
naire has been associated with reduced survival and, while there was
no consensus recommendation for use of CFQ-R in routine clinical prac-
tice, a Physical score b 30 could be considered alongside other markers
of shortened survival in the decision to refer for transplant [44,45].
Although FEV1 alone should not determine timing of lung transplant
referral, referral should occur no later than when the non-exacerbation
(“stable”) FEV1 is b30% predicted. Among individuals with a “stable”
FEV1 b 30% predicted in the US, approximately 10% die without LTx
each year after reaching this threshold [1]. For individuals with frequent
exacerbations, it may be difﬁcult to assess a “stable” FEV1, but these in-
dividualsmay beneﬁt from referral (see recommendation #14). Rapidly
declining FEV1 has been shown to predict death without LTx [19,46,47].
A recent study of a sample of individuals with CF who died in the US
found that 38% had a documented “highest” FEV1 that was N40% in the
year prior to death, highlighting that a rapid decline in FEV1 may
precede death for many individuals with CF [48]. Recommendations
#12–16 identify individuals with risk proﬁles highlighted in published
prognostic models [12,14–18].
9. For individuals with CF who are under the age of 18 years, the CF
Foundation recommends lung transplant referral no later than
when:
• FEV1 is b50% predicted and rapidly declining (N20% relative decline
in FEV1 within 12 months).
OR
• FEV1 is b50% predicted with markers of shortened survival (including
those noted in recommendations #12–16).
OR
• FEV1 is b40% predicted.
Individuals with CF frequently transition to adulthood with FEV1
in the normal or only mildly impaired range, with only 5% of
18 year olds having ALD (FEV1 b 40%) in 2015 [49]. Children with
Fig. 1. Lung function thresholds for discussion of lung transplantation and timing of lung transplant referral.
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Table 4
Clinical and educational milestones for lung transplant referral.
At diagnosis of CF and
throughout the life-span
- Individuals with CF should establish and
maintain care with a physician trained in the
natural history, prognosis, and treatment
options for CF.
- Discuss lung transplantation early in the
course of disease as a means to destigmatize
this component of clinical care. Introduce it
as a potential treatment option that prolongs
life for individuals with CF.
- Frame lung transplantation in a positive
manner, instead of as a “last resort” or “fail-
ure of therapy,” because care team attitudes
affect willingness to discuss lung transplan-
tation when it becomes medically necessary
for individuals with CF.
- Utilize up-to-date, CF speciﬁc, resources
when providing lung transplant outcomes
information.
When lung function declines
to FEV1 b 50% predicted
- Discuss values and goals of care.
- Consider having a CF Clinic appointment
dedicated to advanced care planning.
- Implement all indicated medical therapies to
optimize lung function and overall health.
- Discuss ways to optimize health/lung func-
tion to delay lung transplantation, and the
importance of adherence pre- and post--
transplant.
- Optimize body mass index (BMI) with
appropriate nutrition interventions.
- Initiate discussion regarding lung transplan-
tation; early discussion gives individuals with
CF time to consider lung transplantation
when it is not urgently needed.
- Note that lung transplant referral is not an
event, it is a process that begins with
informed discussions of beneﬁts, risks,
indications, and contraindications.
- Elicit and address CF-related concerns about
lung transplantation, such as: fear, shame,
and giving up the “ﬁght” against CF.
- Explain the logistics of lung transplantation
at the “home” CF Center.
- Assess for potential barriers to transplant:
medical, psychosocial, ﬁnancial.
- Discuss potential geographic barriers to lung
transplant (e.g. potential need to relocate,
distance to travel for evaluation, insurance
limitations to lung transplant center options
for coverage).
- Acknowledge differences in clinical outcomes
and the potential need for increased support
for individuals with disadvantaged
backgrounds.
When lung function declines
to FEV1 b 40% predicted
- Increase frequency of CF clinic visits (e.g.
more often than quarterly), if indicated, to
address contributing factors.
- Emphasize the importance of nutrition, dia-
betes control, physical conditioning, self-care,
mental health, adherence, and social support
and correlate them with clinical outcomes
and implications for candidacy for transplant.
- Evaluate for markers of shortened survival
using 6-min walk test (6MWT), nocturnal
oximetry, blood gas, and echocardiogram.
- Assess for organisms with implications for
transplant candidacy (such as:
nontuberculous mycobacteria, fungus, and
Burkholderia species).
- Referral for individuals with markers of
increased severity of disease (e.g. 6MWT
distance b400 m, supplemental oxygen
requirement, hypercarbia, pulmonary hyper-
tension, adults with BMI b18). Discuss impli-
cations for decreased survival in the presence
of markers of increased severity of disease as
the rationale for referral to consider lung
transplantation.
- In the presence of CF-related liver disease,
identiﬁcation of liver cirrhosis (e.g. abdomi-
nal ultrasound) may affect the timing and/or
transplant center of choice for referral.
Chronic kidney disease may warrant consid-
eration of lung-kidney transplant. Early com-
munication with partnering transplant
centers is important in the case of a potential
need for multiple organ transplantation.
- Referral for all individuals under 18 years
of age.
When lung function declines
to FEV1 b 30% predicted
- Referral for all individuals.
- Continue at least annual monitoring for
markers of shortened survival. Individuals
with CF can have prolonged survival with
FEV1 b 30% predicted, but it is important to
continue monitoring for complications of CF
that increase the risk of death without lung
transplant.
- Update the local transplant center every
6 months or with clinical changes.
Modiﬁable barriers to lung
transplantation
- Malnutrition (BMI b18 kg/m2 for adults or
BMI b 5th percentile for children) may be a
contraindication to lung transplantation, but
is modiﬁable. As lung disease progresses,
malnutrition becomes more prevalent. Rec-
ommend use of oral supplements and the
Enteral Tube Feeding Guidelines for manage-
ment of malnutrition.
- CF-related diabetes is associated with
increased pulmonary exacerbations, weight
loss, and lung function decline. Suboptimal
management of diabetes may be a marker of
non-adherence and treatment could slow
disease progression. Diabetes control should
be optimized to maximize medical manage-
ment of advanced CF and minimize trans-
plant-associated risk.
- Chronic opiate use may impair post-lung
transplant pain management and may be a
contraindication at certain centers.
- Substance use has been associated with
worse post-transplant outcomes and there
are center-speciﬁc practices related to sub-
stance use.
- Promote strategies to optimize adherence, as
many transplant centers consider non-adher-
ence to medical care a relative (and some-
times absolute) contraindication to listing/
transplant.
- Early referral permits education and contract
setting, if needed, and an opportunity to
assess capacity for adherence.
- Anxiety and depression are prevalent in indi-
viduals with CF, become more prevalent with
advanced lung disease, and can impair recov-
ery from transplant, especially if inadequately
treated. Identify and treat mental health
issues that may negatively impact transplant
candidacy and outcomes.
- Address psychosocial barriers such as: care-
giver support, ﬁnances, and health literacy.
Special considerations − Geographic and program-speciﬁc donor
availability may inﬂuence the timing of list-
ing and choice of transplant center.
− Insurance coverage may limit access to spe-
ciﬁc transplant centers.
− Complexity of surgical procedure may inﬂu-
ence the choice of transplant center.
− Center-speciﬁc practices are dynamic and
may change over time.
The following may impact lung transplantation
candidacy depending on transplant center-speciﬁc
practices:
- Certain infections (Burkholderia cenocepacia,
Burkholderia gladioli, Burkholderia dolosa,
Mycobacterium abscessus, Scedosporium
proliﬁcans)
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CF tend to have reduced survival compared to adults with the same
FEV1% predicted. For this reason, expert consensus was that children
with CF (under age 18 years) should be referred for LTx at an earlier
FEV1 threshold than the average adult individual [46]. For children
with markers of increased disease severity (including those noted
in recommendations #12–16) consideration for referral prior to the
FEV1 b 40% threshold is recommended. Referral at a higher FEV1
threshold for this younger population gives more time to address
modiﬁable barriers. Additionally, there are a limited number of trans-
plant centers with pediatric experience, which further contributes to
the need for early referral in order to gain insurance approvals and
access to these centers.
10. For individualswith CF and an FEV1 b 40% predicted, the CF Founda-
tion recommends an annual 6-min walk test (6MWT), assessment
of need for supplemental oxygen, and venous blood gas to
screen for markers of severe disease that may warrant transplant
referral.
The 6-min walk test (6MWT) distance is used regularly in
Canada, Ireland and other parts of the world to assess the clinical sta-
tus of individuals with advanced/deteriorating CF-related lung dis-
ease [50,51]. Expert consensus was that annual testing with a
6MWT, an assessment for supplemental oxygen requirement, and ve-
nous blood gas (VBG) would provide clinically meaningful data for
patients with ALD, based on a “stable” FEV1 b 40% predicted
(Table 5). Assessment for supplemental oxygen requirement (SpO2
b 88% or PaO2 b 55 mmHg) should occur at rest, with exertion, and
during sleep [12,52–54]. An annual VBG should be used to screen
for hypercarbia, and if PvCO2 is elevated (PvCO2 N 56 mmHg), a con-
ﬁrmatory arterial blood gas (ABG) should be obtained. In the pediat-
ric population, begin to perform testing when the “stable” FEV1
b 50% predicted (Table 5).
11. For individuals with CF who are 18 years of age and older with FEV1
b 40% predicted, the CF Foundation recommends a baseline echo-
cardiogram to screen for pulmonary hypertension.
Pulmonary hypertension is common in individuals with advanced
CF-related lung disease [43,54–57], but its presence is rarely identiﬁed
prior to evaluation for LTx. Repeat echocardiogram should be consid-
ered for individuals with worsening clinical status. In the pediatric pop-
ulation, perform baseline echocardiogram when the FEV1 is b50%
predicted.
12. The CF Foundation recommends lung transplant referral, regardless
of FEV1, when there are markers of shortened survival, including:
• 6MWT distance b400 m
OR
• hypoxemia (at rest or with exertion)
OR
• hypercarbia (PaCO2 N 50 mmHg, conﬁrmed on arterial blood gas)
OR
• pulmonary hypertension (PA systolic pressure N 50 mmHg on echo-
cardiogramor evidence of right ventricular dysfunction in the absence
of a tricuspid regurgitant jet)
Adults with “stable” FEV1 N40% predicted are unlikely to have these
data available unless their respiratory symptoms are out of proportion
to their FEV1.
- Renal insufﬁciency
- Liver disease
- Critical or unstable clinical condition (e.g.
mechanical ventilation or ECMO)
- Cardiac dysfunction
- Prior thoracic surgery
- Prior lung transplantation
- History of cancer
- Physical inactivity or deconditioning
Decision to initiate lung
transplant referral
- It is important not to rely solely on the FEV1
for timing of referral. Incorporate other
markers of shortened survival into the refer-
ral decision: hypoxemia, hypercarbia, short-
ened 6MWT distance, increasing
frequency/severity of exacerbations, low BMI,
pulmonary hypertension, massive
hemoptysis, pneumothorax, female sex, and
short stature.
- Refer early to avoid missing the lung trans-
plant window.
- Refer early to give opportunity to explore
other options if ﬁrst transplant center
declines the individual as a candidate.
- Provide detailed information about clinical
history, markers of disease severity, and
potential contraindications (see CFF.org for a
transplant referral form template).
- The balance of independence versus the need
for social support is especially complex for
adolescents and young adults.
- Acknowledge the stress, expense, invasive-
ness of procedures (e.g. colonoscopy, right
heart catheterization), and waiting involved
with referral and evaluation.
- Discuss insurance and ﬁnancial implications.
- Assess geographic barriers to transplantation
and identify transplant centers where indi-
viduals have the most social support.
- When a referral is “early,” it is an opportunity
to get detailed information about transplant
and serves as a second opinion that could
identify important modiﬁable barriers to
eventual transplantation.
- Referral during a crisis, or rapid decline, may
limit an individual's access to transplant
depending on local transplant center prac-
tices.
- Consider facilitating pre-transplant individu-
al's communication with a CF transplant
recipient (e.g. local network, CFF Peer
Connect, or Lung Transplant Foundation).
Decision to defer listing - In the United States, consult at least two lung
transplant centers prior to determining that
an individual is not a transplant candidate if
the ﬁrst center declines to list the individual
because of a contraindication.
- If an individual is “too early” for listing, then
establish a plan for continued monitoring and
communication with the transplant team.
- Continued communication with the trans-
plant center includes information about
changes in clinical status, social situation, and
goals of care.
Decision to list for transplant - Communicate with the transplant center
about changes in the individual's status while
listed.
- Lung Allocation Score (LAS) is used for deter-
mining lung transplant recipient priority in
the US. Important components of the LAS
include: age, forced vital capacity (FVC),
pCO2, oxygen requirement, BMI, 6MWT
distance, pulmonary arterial pressure, pres-
ence of diabetes, diagnosis, and functional
status.
- Continue to acknowledge the stress, expense,
waiting time, and uncertainty for individuals
awaiting lung transplant.
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The 6MWT distance is associated with death or LTx for individuals
with CF [56,58–60]. The ISHLT recommends referral for LTx evaluation
when the 6MWT distance is b400 m [61]. Although a sub-maximal ex-
ercise test for a majority of individuals with CF, the 6MWT is a marker
of functional status andmaybetter reﬂect limitations experienced by in-
dividuals with ALD than the FEV1 alone.
Supplemental oxygen requirement and/or low PaO2 have been re-
peatedly associated with death without LTx for individuals with CF
[1,12,52,53,56,62]. Hypercarbia is a knownpredictor of death in individ-
ualswith CF [12,16,54,63]. Pulmonary hypertension has been associated
with death without lung transplant [64–66], but echocardiograms are
imperfect at determining the severity of pulmonary hypertension in pa-
tients with ALD andmay identify “false positive” cases [67,68]. In an in-
dividual with FEV1 b 40% whose only marker of increased disease
severity is an elevated PA systolic pressure (N50mmHg), a conﬁrmatory
right heart catheterization may be warranted prior to transplant
referral.
13. The CF Foundation recommends lung transplant referral for adults
with CF with a BMI b18 and FEV1 b 40% predicted while concur-
rently working to improve nutritional status.
Studies have shown low BMI is a risk factor for death without lung
transplantation [1,14,15,18,69,70] and it should be considered amarker
of urgency for lung transplant referral. Additionally, the trajectory of the
BMI (e.g. rapidly declining) is clinically meaningful and may affect
timing of referral. Minimum BMI thresholds vary from center to center
in the US and low BMI should be proactively addressed (see Enteral
Tube Feeding Guidelines) [71] as a modiﬁable barrier to transplant.
While a speciﬁc BMI cutoff is not useful for deﬁning malnutrition in
the pediatric population and a weight-for-age N 10th percentile is a
common goal [72], malnutrition (e.g. BMI less than 5th percentile for
children) is an important modiﬁable barrier to lung transplantation
for children with CF [73] and should be addressed concurrently with
LTx referral for children with ALD.
14. The CF Foundation recommends lung transplant referral for individ-
uals with FEV1 b 40% predicted and N 2 exacerbations per year re-
quiring IV antibiotics or 1 exacerbation requiring positive pressure
ventilation regardless of FEV1.
Increasing number of pulmonary exacerbations is associated with
death without transplant among individuals with ALD, with risk in-
creased in the setting of 1 or more courses of IV antibiotics
[1,13,17,18,74] or the need for hospitalization [14,15,17,18,52]. The
presence of acute hypercapnic or hypoxemic respiratory failure, or
chronic hypercapnic respiratory failure necessitating positive pressure
ventilation (e.g. noninvasive or invasive ventilatory support), in the
hospital or home setting, should prompt referral for LTx regardless
of FEV1.
15. The CF Foundation recommends lung transplant referral for individ-
uals with FEV1 b 40% predicted andmassive hemoptysis (N240mL)
requiring ICU admission or bronchial artery embolization.
Hemoptysis increases the risk for death or LTx [75,76]. Theremay be
an increased risk for hypercapnic respiratory failure and death following
bronchial artery embolization among individuals with ALD [77]. It is ex-
pert consensus that among individuals with CF and FEV1 between 30%
and 40% predicted, an episode of hemoptysis leading to ICU admission
and/or bronchial artery embolization should prompt referral for LTx
evaluation. Individuals referred for hemoptysis may have risk that is
not captured in the lung allocation score (LAS), andmassive hemoptysis
may occurwithoutwarning, potentially prompting lung transplant cen-
ters to request an exception to the LAS. Additionally, individuals with CF
and FEV1 N 40% may also warrant LTx evaluation if episodes of hemop-
tysis are frequent and severe.
16. The CF Foundation recommends lung transplant referral for individ-
uals with FEV1 b 40% predicted and pneumothorax.
The occurrence of pneumothorax is more frequent among individ-
uals with CF and severe pulmonary impairment (FEV1 b 40%) and
older age. Pneumothorax leads to an increased number of hospitaliza-
tions and number of days spent in the hospital, and an increase in
2-year mortality [78,79]. Recurrent pneumothorax is an indication
for referral for LTx in the ISHLT recommendations for individuals with
CF [61]. Furthermore, consultation with a transplant surgeon at a
partnering center is recommended prior to non-urgent treatment of
pneumothorax (e.g. surgical or medical pleurodesis), as these interven-
tions may impact surgical planning for LTx.
17. For females with CF, especially those who are younger, the CF
Foundation recommends special consideration for lung transplant
referral even when other thresholds have not been met.
There is a persistent gender gap in survival for individuals with CF
[1,12–15,62,80,81] and this recommendation aims to focus providers
on the increased risk of death for females with CF. The increased risk
of death for females is limited to the pre-transplant setting, as post-
transplant survival is not worse for females compared to males with
CF [80]. Special consideration for LTx referral is recommended for fe-
males who are younger, have CF-related diabetes, rapidly declining
FEV1, or rapidly declining BMI.
18. For individuals with short stature (height b162 cm), the CF Founda-
tion recommends special consideration for lung transplant referral
even when other thresholds have not been met.
Individuals with shorter stature (under 162 cm) have an increased
risk of death on the lung transplant waitlist [82,83]. This disadvantage
is at least partially explained by the difﬁculties in ﬁnding donor lungs
of the correct size and is of particular importance among pediatric
lung transplant candidates. This recommendation aims to focus CF pro-
viders on the potential for a longwait time and the need for early refer-
ral of shorter individuals with CF.
19. The CF Foundation recommends CF clinician consultationwith local
and geographically distant lung transplant centers for individuals
with microorganisms that may pose a risk for lung transplantation
(e.g. Burkholderia cepacia complex, nontuberculous mycobacte-
rium, certain molds such as scedosporium).
Infection with certain microorganisms (e.g. Burkholderia cepacia
complex, nontuberculous mycobacterium, molds such as scedosporium,
multi-drug resistant or increasingly resistant microorganisms) is
associated with worse outcomes following lung transplantation
[18,61,84–89]. These microorganisms may be considered absolute con-
traindications at some transplant programs and acceptable at others
Table 5
Committee's consensus for testing recommendations for individuals with FEV1 b 40%
(adults) or FEV1 b 50% (pediatrics).
Test Action
6-min walk test Annual evaluation
Refer if distance b400 m (1,312 ft)
Refer in the presence of rest or exertional supplemental oxygen
requirement
Venous blood
gas
Annual evaluation
Perform arterial blood gas if venous pCO2 N 56 mmHg
Refer if arterial pCO2 N 50 mmHg
Echocardiogram Assess baseline estimate of pulmonary pressure
Refer if PA systolic pressure N 50 mmHg or evidence of right
ventricular dysfunction in the absence of a tricuspid regurgitant
jet
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based on program experience and risk aversion. Similarly, infection
with a particular organismmay not in and of itself be considered an ab-
solute contraindication by a program, but if combined with other risk
factors, may be a reason an individual is declined for LTx. Institution-
speciﬁc microbiological contraindications shift over time, so it is impor-
tant not to make assumptions about transplant candidacy based on
prior practice.
20. Before determining that an individual is not a transplant candi-
date the CF Foundation recommends consultation with at least
two transplant centers, one of which should have experience
addressing the individual's potential contraindications to
transplantation.
While there are established international consensus recommenda-
tions for the selection of lung transplant candidates, published by the
ISHLT [61], each lung transplant programhas developed its own speciﬁc
criteria for transplant candidacy and listing. Individuals who are de-
clined at one transplant center may be deemed suitable at another cen-
ter. In the US, criteria differ widely based on institutional experience,
resources and risk thresholds. In particular, some high-volume lung
transplant programswill consider individualswith renal or liver disease
(potentially for multi-organ transplant) or pathogenic microorganisms
that are considered absolute contraindications at other programs.
Transplant center practices evolve over time, so communicating with
multiple transplant programs maximizes access to current practice.
Once a candidate has been denied transplant by the insurance
provider's preferred transplant center, an appeal can often result in
that person being granted access to a center that will consider the indi-
vidual as an appropriate candidate. While it may be ﬁnancially infeasi-
ble for an individual to travel to a geographically distant transplant
center, it is important to consider this option for those who are declined
for LTx locally. Consultation (Table 1) with a transplant center with ex-
perience addressing an individual's potential contraindications to LTx
would inform the individual, and the CF care team, without necessarily
involving an in-person visit to the center. The US has a unique
healthcare system, with N60 lung transplant centers, and this recom-
mendationmay not easily generalize to countries with fewer transplant
centers.
21. For transplant candidates, the CF Foundation recommends com-
munication between the CF and lung transplant care teams at
least every 6 months and with major clinical changes.
Early referral for LTx allows individuals with CF to establish a rela-
tionship with the transplant team, obtain transplant speciﬁc education,
and identify and modify barriers to transplant. For individuals with CF
deemed “too early” for listing, ongoing communication at set time inter-
vals will allow for continued assessment of disease progression (e.g.
development of markers of increased disease severity noted in rec-
ommendations #12–16; signiﬁcant clinical events) and readiness for
transplant. Signiﬁcant clinical events include, but are not limited to:
exacerbation requiring IV antibiotics (especially if increasing in
frequency), hospitalization, increase in oxygen requirement, non-
invasive positive pressure or mechanical ventilation for respiratory
failure, new CF-related diabetes, new sputum microbiology (e.g.
new Burkholderia or nontuberculous mycobacterium), signiﬁcant de-
cline in 6MWT or FEV1. It is beneﬁcial for all members of the inter-
disciplinary team (social worker, mental health coordinator,
dietician, physical therapist, respiratory therapist and nurse coordina-
tor) to share information affecting an individual's candidacy with
their counterparts as different information is disclosed to different
team members.
For individuals deferred due to barriers, communication should
highlight progress toward addressing barriers to transplant. It is critical
for the transplant team to be aware of changes in clinical status, which
may affect transplant candidacy as well as timing for listing. Open
lines of communication between the CF and lung transplant care
teams regarding patients who are listed or approaching listing are
vital if an individual has a sudden deterioration. Geographic and
program-speciﬁc donor availability and waitlist times may inﬂuence
the timing of listing. Further, certain characteristics such as height,
chest cavity size, ABO blood type and human leukocyte antigen (HLA)
sensitization may result in challenges ﬁnding a suitable donor and im-
pact timing for listing. Finally, local lung transplant center practices
will necessarily inﬂuence how CF providers interpret and implement
these consensus recommendations.
4. International considerations
Outside of the US, there is a broadly similar experience with delays
in referral for LTx. Both European [2] and Australian [90] studies show
that many individuals die without receiving LTx. It is likely that similar
barriers to LTx seen in the US exist in many countries and guidelines
for timely referral for lung transplant assessment are welcome. In addi-
tion to the barriers outlined earlier in this statement, there are a number
of unique challenges in Europe as many of the smaller European coun-
tries do not have a transplant program and must refer to neighboring
countries. This leads to further barriers such as inability of very sick in-
dividuals to travel (often signiﬁcant distances by air), language and cul-
tural difﬁculties throughout the transplant process, and complexities of
cross-country funding and follow-up. Even in countries with well-
established programs, many individuals with CF die without receiving
LTx [2]. In the UK, in a recent survey of 28 specialty CF centers [91]
22% of respondents expressed concerns that LTxwas discussedwith pa-
tients too late and 19% expressed concerns that individuals with CF
were referred for transplant assessment too late. Barriers to referral in
the UK included patient refusal, poor-adherence and psychological
readiness as well as unexpected rapid clinical deterioration or the pres-
ence of signiﬁcant comorbidities/infections that could preclude trans-
plant. In France, with a well-developed National Lung Transplant
Program, including the introduction of an emergency transplant pro-
gram in 2007, 50% of all CF deaths occur without lung transplantation
of which 72% had at least one indication for transplant and were not
on the active transplant list [2]. Although the majority of these individ-
uals were in the process of lung transplant assessment or had been de-
clined for LTx, 39% of these potentially eligible individuals with CF had
never been considered for transplant [2]. A subsequent survey of French
centers [92] proposed an earlier structured approach to transplant as-
sessment including improved patient and caregiver education and ear-
lier discussions of transplant options. These studies, in countries with
well-established transplant programs and specialized CF centers, high-
light that transplant referral challenges are worldwide and that barriers
to early referral need to be identiﬁed and overcome.
5. Potential impact of CFTR modulators
Consideration of the effect of cystic ﬁbrosis transmembrane conduc-
tance regulator (CFTR)modulator therapy on these consensus guideline
recommendations is important because there is growing evidence that
CFTR modulators improve outcomes for a majority of individuals with
CF [93–96] and may deliver a sustained beneﬁt over time [97]. While
CFTR modulators may change the trajectory of lung function decline,
for the foreseeable future there will be many individuals with CF and
ALD. There is no data describing survival with ALD in the era of
highly-effective CFTRmodulator therapy. In the setting ofmarkers of in-
creased disease severity (e.g. FEV1 b 30% predicted, or those noted in
recommendations #12–16) these consensus guidelines should guide
discussions about LTx and decisions about the timing of referral. LTx re-
ferral should not be delayed based on anticipated availability or effect of
current or future CFTR modulators.
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6. Conclusions and Next Steps
Survival for individuals with CF has improved dramatically over
the past few decades and this improvement is expected to accelerate
with new agents that address the cellular defect in CF. Nevertheless,
the majority of individuals with CF still eventually succumb to their
lung disease. LTx has the potential to extend survival for individuals
with CF. Despite this fact, evidence indicates that many individuals
with CF who die from respiratory disease are never referred for
transplant [2,27]. Presumably, some deaths may have been prevented
if LTx had been considered and a referral made. Available data sug-
gests the reasons for non-referral may not be due to absolute contra-
indications to transplant [2,29]. Research on factors contributing to
lack of transplant referral for individuals with CF and FEV1 b 30%
or those with higher lung function who die of respiratory disease is
warranted. There is a potential application for quality improvement
methodology to improve the LTx referral process in a systematic
manner.
These guidelines are intended to help CF providers appropriately
counsel their patients about LTx and decrease the number of individuals
with CF who die from lung disease without consideration of LTx. The
journey through referral, evaluation, listing and transplantation is
fraught with physical and psychosocial challenges for the individual
and their family. LTx requires careful consideration and is not the right
therapy for all individuals with advanced CF-related lung disease. It is
the responsibility of both the CF and the transplant teams to provide
support through this process. Many of the barriers to LTx can be over-
come if identiﬁed and addressed early enough in the course of the dis-
ease to permit adequate time for resolution. While data are limited,
there is a growing body of literature to support the use of FEV1 com-
bined with other physiologic parameters including pulmonary artery
pressure, blood gas (to detect hypoxemia or hypercarbia), trajectory
of lung function and nutritional status to determine appropriate timing
of referral and listing for transplant. While most individuals who meet
these Consensus Guidelines' criteria for referral will be too early for list-
ing, it is important to recognize that referral does not necessarily
prompt a full evaluation or listing, but instead gives individuals with
CF, their families, and providers access to the expertise of the LTx
team and the opportunity to fully consider LTx as a treatment option.
The individual with CF will then have sufﬁcient information to make a
decision if the need for LTx arises.
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